RAD51 and neoplasm: The stabilized mutant BRCA1 protein confers cisplatin resistance due to interaction with PALB2-BRCA2-RAD51, which is essential for RAD51 focus formation.Interestingly, it has been demonstrated that mutation RAD51C/RAD51D in post progression tumor biopsy samples collected from patients in ARIEL2 Part 1, a phase II study of the PARPi rucaparib as treatment for platinum-sensitive, relapsed ovarian carcinoma is a mechanism of restoration of HR and acquired PARPi resistance [35,37,38,39].